Literature DB >> 1935311

Hypercalcemia induced by parathyroid hormone-related protein from lung cancer tissue.

H Tanaka1, S Kobayashi, A Masaoka, S Honda, K Yamaguchi.   

Abstract

Most lung carcinomas with hypercalcemia are usually unresectable. However, this case was resectable and the serum calcium level was normalized after the operation. Messenger RNA of the precursor of PTH-related protein (PTHrP), a substance that may be one of the causes of hypercalcemia in malignant neoplasms, was identified in the tumor tissue of the patient. The patient was a 60-year-old man with squamous cell carcinoma originating from the posterior basal segment of the left lung and invading the main bronchus and left atrium. The serum calcium level was 14.3 mg/dl, preoperatively. Pneumonectomy with partial left atrium resection was carried out and the serum calcium level became normal postoperatively. Three months following the operation, this measurement was 9.4 mg/dl, but increased to 16.2 mg/dl at four months, at which time he experienced lumbago and chest pain. The patient died eight months following the operation from uncontrollable renal failure. In the tumor tissue, mRNA of PTHrP precursor was identified. To our knowledge, this is the first case of lung cancer that could be resected, and in which PTHrP was found present.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1935311     DOI: 10.1378/chest.100.5.1451

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

1.  Successful stereotactic body radiation therapy for stage I non-small cell lung cancer with malignant hypercalcemia - Case report.

Authors:  Thinh Chau; Allan Y Chen
Journal:  J Radiosurg SBRT       Date:  2018

2.  A surgical case of lung cancer with poor general status associated with parathyroid hormone-related protein.

Authors:  Toshiko Kamata; Eitetsu Koh; Atsuko Masunaga; Asako Okabayashi; Mizue Hasegawa; Hideki Katsura; Kenzo Hiroshima; Yasuo Sekine
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.